抗人 ZFP90 抗体对
01AB00999
ZFP90 zinc finger protein (ZFP90) is a zinc finger protein that contains 13 zinc finger domains and a KRAB domain. It functions as a transcriptional regulator, inhibiting the repressor activity of REST by preventing its DNA binding, thereby derepressing transcription of REST target genes. ZFP90 is involved in various biological processes, including cardiac development, neuronal differentiation, and immune regulation. It acts as a bridge between FOXP3 and the corepressor TRIM28, playing a role in the transcriptional repressor activity of FOXP3 in regulatory T-cells. ZFP90 has been implicated in several diseases, including colorectal cancer. It is also associated with systemic lupus erythematosus, with its expression levels correlating with specific clinical characteristics. Additionally, ZFP90 knockdown has been shown to promote cisplatin sensitivity in ovarian cancer cells by regulating the Nrf2/HO-1 pathway.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- ZFP90
- 基因别名
- KIAA1954; ZNF756
- 蛋白别名
- ZFP90 zinc finger protein; ZFP90
- UniProt
- Q8TF47
- 物种
- Human
产品详情
- 靶点名称
- ZFP90
- 蛋白名称
- ZFP90 zinc finger protein
- 蛋白别名
- Zinc finger protein 90 homolog; Zfp-90; Zinc finger protein 756
- 靶点基因名
- ZFP90
- 基因别名
- KIAA1954; ZNF756
- UniProt
- Q8TF47
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
ZFP90 zinc finger protein (ZFP90) is a zinc finger protein that contains 13 zinc finger domains and a KRAB domain. It functions as a transcriptional regulator, inhibiting the repressor activity of REST by preventing its DNA binding, thereby derepressing transcription of REST target genes. ZFP90 is involved in various biological processes, including cardiac development, neuronal differentiation, and immune regulation. It acts as a bridge between FOXP3 and the corepressor TRIM28, playing a role in the transcriptional repressor activity of FOXP3 in regulatory T-cells. ZFP90 has been implicated in several diseases, including colorectal cancer. It is also associated with systemic lupus erythematosus, with its expression levels correlating with specific clinical characteristics. Additionally, ZFP90 knockdown has been shown to promote cisplatin sensitivity in ovarian cancer cells by regulating the Nrf2/HO-1 pathway.